Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company based in San Diego, California, dedicated to developing next-generation oncology therapies. The company's pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs), targeting key enzymes involved in cell cycle regulation and specific cancer markers. Avenzo's lead drug candidates, including AVZO-021 and AVZO-023, are being studied for the treatment of advanced solid tumors and HR+/HER2- metastatic breast cancer, while its ADCs focus on bispecific targeting of cancer cells.
Leadership & Board
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $60M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $60M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 22, 2025 | Series B | $60.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| OrbiMed | Series B |
| TF Capital | Series B |
| Deep Track Capital | Series B |
| Sands Capital | Series B |
| Delos Capital | Series B |
| Longwood Fund | Series B |
| SR One | Series B |
| Surveyor Capital | Series B |
Similar Companies
A snapshot of private companies similar to Avenzo Therapeutics, helping you discover and navigate related company profiles.
